Company Overview and News

 
PRESS DIGEST- Financial Times - Sept 17

2018-09-17 reuters
Sept 17 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.
AVV.CL AV DB UL AV.A AV.B UNLYF ULVR UN AV UNLNF AIVAF AVV

7
Structural Changes Won’t Change the Narrative for Unilever Stock

2018-09-13 investorplace
Unilever (NYSE:UL, NYSE:UN) appears poised for a new future under a simplified business framework. The provider of household brands such as Lipton tea, Dove soap, and Ben & Jerry’s ice cream wants to redefine its corporate structure. Although this will leave one Unilever stock instead of two, I see no other differences easily visible to shareholders.
GIS UL PG UN CL UNLYF ULVR KHC UNLNF

7
Unilever to be forced from U.K.’s FTSE-100

2018-09-12 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
UL UNLYF ULVR UN RYCEY BP BP.A UNLNF BP.B BP KHC BPAQF RYCEF

 
UN or CLX: Which Is the Better Value Stock Right Now?

2018-09-12 zacks
Investors looking for stocks in the Soap and Cleaning Materials sector might want to consider either Unilever NV (UN - Free Report) or Clorox (CLX - Free Report) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
UL UN UNLYF ULVR UNLNF

 
Unilever's Dutch entity to replace parent company on FTSE Russell

2018-09-11 reuters
(Reuters) - FTSE Russell said on Tuesday consumer goods giant Unilever Plc (ULVR.L) (UNc.AS) would be deleted from all its indexes by the end of the year and replaced by New Unilever NV.
UL UN UNLYF ULVR UNLNF

 
Unilever's Dutch entity to replace parent company on FTSE Russell

2018-09-11 channelnewsasia
FTSE Russell said on Tuesday consumer goods giant Unilever Plc would be deleted from all its indexes by the end of the year and replaced by New Unilever NV.
UL UN UNLYF ULVR UNLNF

 
UNLYF / Unilever, PLC 424B5 (Prospectus)

2018-09-05 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS
UNLYF

 
UNLYF / Unilever, PLC 424B5 (Prospectus)

2018-09-04 sec.gov
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS
UNLYF

15
From Unilever to Ford, companies in Venezuela cling on by cutting products

2018-08-31 channelnewsasia
Unilever's factory in the outskirts of the northern Venezuelan city of Valencia once bustled with activity as it produced everything from soap to toothpaste for one of South America's wealthiest economies.
UL UNLYF ULVR UN SKG KCDMY KMB UNLNF KMB.WI SMFKY GM CLX

15
From Unilever to Ford, companies in Venezuela cling on by cutting products

2018-08-31 reuters
CARACAS/VALENCIA, Venezuela (Reuters) - Unilever’s factory in the outskirts of the northern Venezuelan city of Valencia once bustled with activity as it produced everything from soap to toothpaste for one of South America’s wealthiest economies.
UL UNLYF ULVR UN SKG KCDMY KMB UNLNF KMB.WI SMFKY GM CLX

12
Mizuho’s new leader Tatsufumi Sakai gears up to reform struggling mega-bank

2018-08-24 japantimes.co.jp
When Tatsufumi Sakai was named chief executive and president of Mizuho Financial Group this year, many bankers and investors were surprised.
MZHOF UL UNLYF ULVR UN SMFG UNLNF SMFNF XRX BABA 8316 8306 MUFG 8411 MBFJF MTU MFG

3
General Mills changing Nature Valley labels after lawsuit's pesticide claim

2018-08-23 reuters
(Reuters) - General Mills Inc agreed to stop calling the oats in its Nature Valley granola bars 100 percent natural to settle a lawsuit by three consumer groups that said the bars contained small amounts of the pesticide commonly known as RoundUp.
GIS UL UN UNLYF ULVR MON UNLNF

 
New CEO at Ben & Jerry’s Plans to Whip Up Activism, ‘Whirled Peace’ - WSJ

2018-08-15 wsj
Ben & Jerry’s, the ice-cream maker known for its social advocacy as much as its chunk-filled flavors, has a new chief executive who is promising to ramp up the brand’s corporate activism.
UL UN UNLYF ULVR UNLNF

109
Tracking Gardner Russo & Gardner Portfolio - Q2 2018 Update

2018-08-15 seekingalpha
The top three 13F stakes are Berkshire Hathaway, Mastercard, and Nestle, and they add up to ~34% of the portfolio.
DGEAF ULVR BATS RI UNLNF AMZN CMCSK MO SWGAF UNLYF BRK.A BABA HEIO SWGAY SWGNF GOOGL CFRUY AHBIF MLM JCDXF WFCNP PM FMX CCV AXP CCZ 4162 GOOG CFRHF JCDXY BF.B BF.A DEO WFC BUD UL UN CMCSA MA V CCV.CL BFA

4
Publicis Media appoints Mindshare’s Sejal Shah as managing partner

2018-08-13 livemint
New Delhi: Publicis Media India on Monday announced the appointment of Sejal Shah as managing partner and head of its media-trading arm Publicis Media Exchange (PMX-Mainline). Shah joins the agency from Mindshare Fulcrum, a unit of WPP-owned media agency Mindshare where she was serving as trading head (South Asia) for the Unilever Plc account.
UL AXB UNLYF ULVR UN DABUR NESTLEIND UNLNF DBRQY 532215 AXBKY AXBA 500096 AXISBANK KHC 500790 NSZTY

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 904784501